.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average consequence of 11 months, patients along with metastatic intestinal tumors that acquired biomarker-matched therapies based upon circulating tumor DNA profiling revealed a greater professional benefit than those obtaining unparalleled treatment.